England under-19 star Simran Jhamat has been backed to “inspire and the lead the way” for the next generation of female British South Asian footballers.
Jhamat, who has played for teams like Liverpool, Coventry and Leicester, became the first Punjabi girl to score at competitive level for England's U17s when she netted in a 6-0 Euro qualifying win against Slovakia.
The 20-year-old now plays for Lewes FC in the FA Women’s Championship. Her former Liverpool manager Vicky Jepson is excited by the prospect of where Jhamat’s flourishing career will take her.
"She's a fantastic role model and she's still only young so nobody knows where she is going to reach in the future," Jepson told Sky Sports News.
"For other females to look up to Sim, who is inspiring and leading the way [is so important]. She's showing it doesn't matter where you come from and what your background is, if you really want to achieve your goals and you work hard just like Sim has - and she's still on her journey to reach the top - then the world is your oyster."
According to government data released last year, British Asian women are the least active social group in the UK.
Just 61.5 per cent of females aged 16 years and over are classed as ‘physically active’ in the UK. For Asian women, it is only 49.1 per cent.
Jepson hopes role models such as Jhamat can help improve these statistics.
The 20-year-old from Walsall was spotted playing for local club Sporting Khalsa at junior level before being signing for Aston Villa's Girls' Centre of Excellence where she spent seven seasons before joining Liverpool in 2017.
Jepson coached Jhamat with England’s youth teams and gave her her debut with two-time FA Women’s Super League champions Liverpool in 2019.
Simran Jhamat (Photo by Catherine Ivill/Getty Images)
"Simran was a pleasure to work with," Jepson added.
"I worked with her in the U21s at Liverpool and also with the England U21s, so I got to see her club and an international environment as a youth player.
"When I stepped up as the first-team manager (at Liverpool in 2018) I got to see first-hand. I brought her in to train to see how she would cope in a senior environment.
"She was great to work with as a young player who had a growth mindset and wanted to be better, and I thoroughly enjoyed working with her for the time I did.
"What I saw from her in the international setup, playing against top teams like France, Spain, USA, convinced me she could compete. She was definitely worth giving a chance to have a debut for Liverpool."
According to a report commissioned by the Football Supporters’ Association (FSA) and Beyond Entertainment (BE) last year, British Asians make up seven per cent of the whole population but only 0.25 per cent of professional footballers.
Kevin Coleman, the FA equality and diversity manager, is one of the people working on increasing the number of British Asian men and women in the professional game.
“Asian inclusion is a crucial part of the FA’s wider diversity and inclusion strategy as we recognise the importance of making football at all levels as truly representative and diverse as our society is,” he said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.